M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug PharmaphorumServier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.Rare DiseaseRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaphorum Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten. Rare Disease Read full story Post navigation Previous: ASCO: Summit reached with China lung data but new climb begins to prove global benefitNext: CordenPharma inks AmbioPharm buyout to continue peptide production expansion Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026